ABCL - AbCellera Biologics Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD

AbCellera Biologics Inc.

2215 Yukon Street
Vancouver, BC V5Y 0A1

Full-time employees525

Key executives

NameTitlePayExercisedYear born
Dr. Carl L.G. Hansen Ph.D.CEO, Pres & Chairperson711.47k1.85M1975
Mr. Andrew Booth M.B.A.Chief Financial Officer642.42k510.82k1974
Dr. Veronique Lecault Ph.D.COO & Director645.07kN/A1985
Mr. Tryn T. Stimart Esq., J.D.Chief Legal Officer, Chief Compliance Officer & Corp. Sec.644.4kN/A1970
Mr. Neil Aubuchon M.B.A.Chief Commercial Officer684.81kN/A1970
Dr. Ester Falconer Ph.D.Chief Technology OfficerN/AN/A1975
Mr. Bo Barnhart Ph.D.Scientific DirectorN/AN/AN/A
Ms. Tiffany Chiu B.Sc., Ph.D.VP of CommunicationsN/AN/AN/A
Alexandra Weirich M.Sc.Mang. of Marketing & CommunicationsN/AN/AN/A
Graham Craig M.Sc.Director of Corp. Devel.N/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Corporate governance

AbCellera Biologics Inc.’s ISS governance QualityScore as of 1 June 2023 is 8. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.